This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

White House Push to Stop U.S. Companies Moving Overseas Unlikely to Bear Fruit

NEW YORK (TheStreet) -- On Tuesday, Secretary of the Treasury Jack Lew sent a letter to Dave Camp, Republican chairman of the House Ways and Means Committee, concerning tax reform.

The gist of the letter: Enact new legislation that would stamp out corporate "inversions" where U.S. companies merge with foreign ones and locate the resulting parent company in a foreign country.

The motive for inversions is clear: Corporations want to reduce their tax payments.

Yellen's Dilemma at the Fed -- Get Used to Long-Term Uncertainty

What Would a Tesla/BMW Deal Look Like?

The U.S. has one of the highest corporate tax rates in the world, although many large U. S. corporations reduce their de facto tax rates significantly through various accounting moves such as keeping assets on the books of foreign offices.

The concern in Washington is that inversions will cost the Treasury a bundle in coming years. Congressional staff estimate the cost at $20 billion over the next decade.

But inversions aren't anything new.

The reason why the administration is raising the issue now is that there's a midterm election coming up, and the lame-duck Obama administration, after a string of setbacks, is looking for issues that will resonate and mobilize its base in an to attempt to keep the Senate under Democratic control.

The reason why Democrats picked this particular issue is recent publicity about corporate moves.

In May Pfizer (PFE) attempted to merge with London-based AstraZeneca (AZN).

Note that Mr. Lew's letter asks that the Congress make the new law retroactive to May 2014. Interesting that he picked that particular month.

More recently, there have been discussions between AbbVie (ABBV), the U.S. biopharmaceutical that just was spun off by Abbott Labs (ABT), and Irish drugmaker Shire (SHPG). Ireland would become the new headquarters of the combined companies.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
AAPL $109.18 -2.80%
FB $87.39 -2.80%
GOOG $598.00 -2.70%
TSLA $240.51 -2.90%
YHOO $32.07 0.94%

Markets

Chart of I:DJI
DOW 16,374.76 +23.38 0.14%
S&P 500 1,951.13 +2.27 0.12%
NASDAQ 4,733.4970 -16.4820 -0.35%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs